In lung cancer therapy, anti-angiogenic or anti-inflammatory agents show widespread efficacy across many cancer types, while inhibition of the EGF receptor (EGFR) is mainly effective in the NSCLC sub-population containing activating EGFR mutations [40,47]. The gene discussed is EGFR; the disease is cancer.